Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen declared a quarterly dividend on Thursday, March 7th. Investors of record on Friday, May 17th will be given a dividend of $1.45 per share on Friday, June 7th. This represents a $5.80 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Thursday, May 16th. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen announced that its Board of Directors has authorized a share repurchase program on Friday, February 2nd 2018, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Tuesday, January, 29th. The medical research company reported $3.42 EPS for the quarter, beating the Zacks' consensus estimate of $3.26 by $0.16. The medical research company earned $6.23 billion during the quarter, compared to analysts' expectations of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same quarter in the previous year, the company earned $2.89 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for Amgen.
What guidance has Amgen issued on next quarter's earnings?
Amgen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $13.10-14.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.66. The company issued revenue guidance of $21.8-22.9 billion, compared to the consensus revenue estimate of $22.92 billion.Amgen also updated its FY 2019 guidance to $13.10-14.30 EPS.
What price target have analysts set for AMGN?
17 brokers have issued 12-month price objectives for Amgen's shares. Their predictions range from $179.00 to $234.00. On average, they anticipate Amgen's share price to reach $207.7647 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Has Amgen been receiving favorable news coverage?
News articles about AMGN stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amgen earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN) and Halozyme Therapeutics (HALO).
What other stocks do shareholders of Amgen own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Pfizer (PFE) and Celgene (CELG).
Who are Amgen's key executives?
Who are Amgen's major shareholders?
Amgen's stock is owned by many different of institutional and retail investors. Top institutional investors include Ellis Investment Partners LLC (0.10%), Los Angeles Capital Management & Equity Research Inc. (0.08%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%) and Strs Ohio (0.05%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Merriman Wealth Management LLC, Los Angeles Capital Management & Equity Research Inc., Abner Herrman & Brock LLC, South Texas Money Management Ltd., Avalon Advisors LLC, Pennsylvania Trust Co, Palisade Asset Management LLC and Tibra Equities Europe Ltd. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Hexavest Inc., Pacer Advisors Inc., Cardinal Capital Management Inc., Manning & Napier Group LLC, Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV and Spectrum Management Group Inc.. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $180.48.
How big of a company is Amgen?
Amgen has a market capitalization of $111.17 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.
What is Amgen's official website?
The official website for Amgen is http://www.amgen.com.
How can I contact Amgen?
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.